Image source: Shutterstock

Highlights

  • Pro Medicus reported a 32.16% YoY revenue increase to AUD 100.79 million and a 42.74% surge in net profit to AUD 51.75 million in 1HFY25
  • Its U.S. subsidiary, Visage Imaging, signed a multi-year research partnership with the University of California, San Francisco.
  • The company has maintained 99.90% gross profit margin and reported quick ratio of 7.04x in 1HFY25.

Melbourne-based health informatics firm Pro Medicus Limited (ASX:PME) offers a full range of medical imaging, software, and services to healthcare groups, hospitals and imaging centres. The company has a presence across Europe, North America and Australia. In the six months ended 31 December 2024 (1HFY25), Pro Medicus posted a 32.16% YoY increase in revenue, reaching AUD 100.79 million, compared to AUD 76.26 million in the previous corresponding period. The surge in revenue was attributed to higher sales volumes across its key markets—Australia, Europe, and North America.

Meanwhile, net profit for the period jumped 42.74% YoY to AUD 51.75 million, up from AUD 36.25 million in 1HFY24. This growth in profitability was driven by stronger top-line performance, a decline in net foreign currency losses, and favourable depreciation and amortisation effects.

Supporting these numbers, PME’s gross profit margin remained high at 99.90%. The company also maintained a solid quick ratio of 7.04x.

Operational Developments

On 15 April 2025, Pro Medicus announced a significant development in its research and innovation arm. Its wholly owned U.S.-based subsidiary, Visage Imaging, Inc., entered into a multi-year research partnership with the University of California, San Francisco (UCSF).

Outlook

Looking ahead, Pro Medicus is optimistic about sustaining its growth momentum. The company is banking on a robust pipeline of contracts, a history of significant contract wins, and continued strategic expansion into key healthcare markets.

Top 10 shareholders of PME

The top 10 shareholders of PME collectively hold approximately 52.49% of the company’s shares, reflecting a strong concentration of ownership. The largest individual stakes are held by Anthony Barry Hall and Sam Aaron Hupert, each owning 23.11% of the company.

Share performance of PME

PME finished at AUD 208.680 on 23 April 2025, rising 1.63% in intraday trade. The stock gained 2.2891% over the past week but recorded a 1-month drop of 9.2300% and a 3-month decline of 22.1749%. However, it posted a 6-month gain of 11.0295% and a strong 9-month rise of 51.3051%.

The 52-week high of AUD 298.980 was reached on 13-Feb-2025, while the 52-week low of AUD 102.380 was recorded on 22-Apr-2024.

Support and Resistance Summary

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 23 April 2025. The reference data in this report has been partly sourced from EODHD/Others.

 

Technical Indicators Defined:

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.